Clinical and biochemical characteristics of early depression in Parkinson’s disease
Depression is more prominent in untreated patients in the early phase of the disease than in treated patients who have suffered from Parkinson’s disease more than six years. In depressive Parkinson patients low levels of urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) and an abnormal Dexamethasone Suppression Test were found. Although a reactive component could not be excluded, both pharmacological and biochemical data support the hypothesis that alterations in norepinephrine metabolism could be the cause for depression in Parkinson’s disease.
KeywordsParkinson Patient Motor Disability Dexamethasone Suppression Test Endogenous Depression Early Depression
Unable to display preview. Download preview PDF.
- Cagnasso M, Biondi PA (1974) Gaschromatographic estimation of urinary vanilmandelicacid and 3-methoxy-4-hydroxyphenylethyleneglycol after their purification on Sephadex LH 20. Ital J Biochem 5: 345–355Google Scholar
- Celesia GG, Wanamaker WM (1972) Psychiatric disturbances in Parkinson’s disease. Dis New System 33: 577–583Google Scholar
- Demel I, Schubert H, Unterthiner D (1980) Initialsymptome bei depressiven Erkrankungen. Neurol Psychiat 6: 263–266Google Scholar
- Riederer P, Birkmayer W (1980) A new concept: brain area specific imbalance of neurotransmitters in depression syndrome—human brain studies. In: Usdin E, Sourkes TL, Youdim MBH (eds) Enzymes and neurotransmitters in mental disease. Wiley, New York, p 261Google Scholar